Publications by authors named "Jutta Beier"

Claim this Profile
T
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD.
Dave Singh, Jutta Beier, Carol Astbury, Maria G Belvisi, Carla A Da Silva

Eur Respir J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice - Results of the Non-Interventional DETECT Study.
Tanja Plate, Felix W Friedrich, Jutta Beier

Int J Chron Obstruct Pulmon Dis· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial.
Jutta Beier, Henrik Watz, Zuzana Diamant, Jens M Hohlfeld, Dave Singh

ERJ Open Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
Henrik Watz, Jens M Hohlfeld, Dave Singh, Jutta Beier, Zuzana Diamant

Respir Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.
Kai Michael Beeh, Anne-Marie Kirsten, Ana-Maria Tanase, Alexia Richard, Weihua Cao, Jutta Beier

Int J Chron Obstruct Pulmon Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
Mary N Brown, Rainard Fuhr, Jutta Beier, Hong-Lin Su, Yingxue Chen

Respir Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
Jutta Beier, Robert Mroz, Anne-Marie Kirsten, Ferran Chuecos, Esther Garcia Gil

Int J Chron Obstruct Pulmon Dis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of once-daily abediterol in patients with stable, persistent asthma: a Phase II, randomized, 7-day, crossover study.
Jutta Beier, Rainard Fuhr, Beatriz Seoane, Eric Massana, Gonzalo de Miquel

Pharmacol Res Perspect· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
Kai-Michael Beeh, Jutta Beier, Henning Candler, Thomas Wittig

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma.
Veit J Erpenbeck, Todor A Popov, David Miller, Steven F Weinstein, Sheldon Spector, Jutta Beier

Data Brief· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
Claus Vogelmeier, Pier Luigi Paggiaro, Jordi Dorca, Pawel Sliwinski, Marcel Mallet, Jutta Beier

Eur Respir J· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
Veit J Erpenbeck, Todor A Popov, David Miller, Steven F Weinstein, Sheldon Spector, Jutta Beier

Pulm Pharmacol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abediterol, a novel long-acting β2-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD.
Jutta Beier, Helena Pujol, Beatriz Seoane, Eulalia Jimenez, Carol Astbury

BMC Pulm Med· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal measurement of airway inflammation over one year in children and adults with intermittent asthma.
Frauke Pedersen, Olaf Holz, Frank Kanniess, Stefan Zielen, Johannes Schulze, Jutta Beier

BMC Res Notes· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
Kai-Michael Beeh, Stephanie Korn, Jutta Beier, Dalal Jadayel, Michelle Henley

Respir Med· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study.
Kenneth R Chapman, Kai-Michael Beeh, Jutta Beier, Eric D Bateman, Anthony D'Urzo

BMC Pulm Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
Jutta Beier, Anne-Marie Kirsten, Robert Mróz, Rosa Segarra, Ferran Chuecos

COPD· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhaled pan-selectin antagonist Bimosiamose attenuates airway inflammation in COPD.
Henrik Watz, Daniel Bock, Michael Meyer, Katrin Schierhorn, Karin Vollhardt, Jutta Beier

Pulm Pharmacol Ther· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
Jutta Beier, Jan van Noord, Amanda Deans, Jean Brooks, Claire Maden

Int J Chron Obstruct Pulmon Dis· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of aclidinium bromide in younger and elderly patients with chronic obstructive pulmonary disease.
Stephan de la Motte, Jutta Beier, Karin Schmid, Silvia Pascual, Josep Maria Jansat

Int J Clin Pharmacol Ther· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium.
Kai-Michael Beeh, Jutta Beier, James F Donohue

Respir Res· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol.
Jutta Beier, Kai M Beeh

Int J Chron Obstruct Pulmon Dis· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist.
Kai M Beeh, Jutta Beier

Core Evid· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The short, the long and the "ultra-long": why duration of bronchodilator action matters in chronic obstructive pulmonary disease.
Kai M Beeh, Jutta Beier

Adv Ther· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
Kai M Beeh, Jutta Beier

Adv Ther· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis